공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

세계의 생물제제 안전성 시험 시장 예측(-2026년) : 제품 및 서비스(소모품, 기기, 서비스), 용도(백신, 모노클로널 항체, 혈액제제, 세포 및 유전자 치료 제품), 시험 유형(엔도톡신, 마이코플라스마, 무균 시험), 지역별

Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Application (Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products), Test Type (Endotoxin, Myoplasm, Sterility Test)-Global Forecast to 2026

리서치사 MarketsandMarkets
발행일 2021년 05월 상품 코드 1006544
페이지 정보 영문 179 Pages
가격
US $ 4,950 ₩ 5,875,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,650 ₩ 7,892,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,150 ₩ 9,673,000 PDF (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없지만, 동일 국가의 동일 사업장에 한정되며 해외지점 등은 포함되지 않습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,000 ₩ 11,869,000 PDF (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 생물제제 안전성 시험 시장 예측(-2026년) : 제품 및 서비스(소모품, 기기, 서비스), 용도(백신, 모노클로널 항체, 혈액제제, 세포 및 유전자 치료 제품), 시험 유형(엔도톡신, 마이코플라스마, 무균 시험), 지역별 Biologics Safety Testing Market by Product & Service (Consumables, Instrument, Services), Application (Vaccine, Monoclonal Antibodies, Blood products, Cell & Gene Therapy Products), Test Type (Endotoxin, Myoplasm, Sterility Test)-Global Forecast to 2026
발행일 : 2021년 05월 페이지 정보 : 영문 179 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 생물제제 안전성 시험 시장 규모는 예측 기간 중 12.4%의 CAGR로 추이하며, 2021년 34억 달러에서 2026년에는 62억 달러 규모로 성장할 것으로 예측됩니다.

생물제제 및 바이오시밀러 시장의 성장, 세포배양 오염에 관한 우려의 증가, 생물제제 R&D 및 투자의 증가 등의 요인이 이 시장의 성장을 촉진하고 있습니다. 또한 신흥 시장의 존재 및 아웃소싱의 증가도 참여 사업자에게 큰 성장 기회를 제공할 것으로 예측됩니다.

용도별로는 모노클로널 항체 제조 부문이 2020년에 최대 점유율을 보이고 있습니다. 각종 질환의 유병률 상승, 모노클로널 항체 의약품의 개발에 대한 정부 구상의 활발화 등의 요인이 이 부문의 성장을 촉진하고 있습니다.

세계의 생물제제 안전성 시험 시장을 조사했으며, 시장의 정의와 개요, 밸류체인, 신종 코로나바이러스 감염증(COVID-19) 및 기타 시장 영향요인 분석, 법규제 환경, 특허 동향, 시장 규모의 추이·예측, 제품 & 서비스·시험 유형·용도·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 서론

제2장 조사 방법

제3장 개요

제4장 중요 인사이트

제5장 시장 개요

  • 시장 역학
    • 촉진요인
    • 시장 기회
    • 과제
  • COVID-19의 영향
  • 가격 분석
  • 밸류체인 분석
  • 에코시스템
  • 특허 분석
  • 규제 분석
  • Porter의 산업 분석

제6장 시장 분석·예측 : 제품·서비스별

  • 서비스
  • 소모품
  • 기기

제7장 시장 분석·예측 : 시험 유형별

  • 잔존 숙주세포 유래 단백질(HCP)·DNA 검출 시험
  • 마이코플라스마 시험
  • 멸균 시험
  • 엔도톡신 시험
  • 바이러스 안전성 시험
  • 바이오버든 시험

제8장 시장 분석·예측 : 용도별

  • 모노클로널 항체 제조
  • 백신 제조
  • 혈액·혈액제제 제조
  • 세포·유전자 치료 제품 제조
  • 기타

제9장 시장 분석·예측 : 지역·주요 국가별

  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동·아프리카

제10장 경쟁 구도

  • 개요
  • 시장 순위 분석
  • 기업 평가 매트릭스
  • 신규 기업 : 경쟁 리더십 지도제작
  • 시장 평가 프레임워크
  • 기업의 제품 발자국
  • 기업의 시험 유형별 발자국
  • 기업의 지역적 발자국
  • 기업의 발자국
  • 경쟁 시나리오

제11장 기업 개요

  • 주요 기업
    • CHARLES RIVER LABORATORIES, INC.
    • LONZA
    • THERMO FISHER SCIENTIFIC, INC.
    • MERCK KGAA
    • SGS SA
    • EUROFINS SCIENTIFIC
    • WUXI APPTEC
    • ASSOCIATES OF CAPE COD, INC.
    • BIOMERIEUX SA
    • SAMSUNG BIOLOGICS
    • GENSCRIPT
    • SARTORIUS AG
    • ROCHE DIAGNOSTICS
    • PACIFIC BIOLABS
    • NELSON LABORATORIES, LLC
    • AGILENT TECHNOLOGIES, INC.
    • MARAVAI LIFESCIENCES
  • 기타 기업
    • QIAGEN
    • BIO-RAD LABORATORIES, INC.
    • MICROCOAT BIOTECHNOLOGIE GMBH
    • INVIVOGEN
    • PROMOCELL GMBH
    • ACCUGEN LABORATORIES, INC.
    • FUJIFILM WAKO PURE CHEMICAL CORPORATION
    • ALMAC GROUP

제12장 부록

KSA 21.05.31

The global biologics safety testing market is projected to reach USD 6.2 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 12.4% during the forecast period. The growth of the global biologics safety testing market is driven by factors such as the growth in the biologics and biosimilars markets, growing concerns over cell culture contamination, and rising biopharmaceuticals R&D activities and investments. In addition, emerging markets and increasing biopharmaceutical outsourcing are expected to provide significant growth opportunities for players in the Biologics safety testing market.

"By product segment, the service segment accounted for the largest share of the Biologics Safety Testing market"

Based on product and service, the biologics safety testing market is segmented into consumables, services, and instruments. In 2020, the services segment accounted for the largest market share. The large share of this segment can be attributed to the limited finances of biopharmaceutical manufacturers, capacity constraints, need for reduction in the time to market, complex manufacturing requirements, large investments required for establishing manufacturing facilities, and the increasing drugs pipeline, all of which have prompted the shift towards the outsourcing of biologics safety testing to service providers.

"By application, the monoclonal antibodies manufacturing segment accounted for the largest market share of the Biologics safety testing market "

Based on application, the biologics safety testing market is segmented into monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications. In 2020, the monoclonal antibodies manufacturing segment accounted for the largest market share. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government initiatives for the development of monoclonal antibody drugs.

"Asia Pacific: The fastest-growing region in the Biologics Safety Testing Market"

The Biologics Safety Testing Market in the Asia Pacific region is projected to register the highest growth during the forecast period. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.

"North America accounted for the largest share of the Biologics safety testing market in 2020"

North America accounted for the largest share of the biologics safety testing market in 2020. Rapid growth in the biopharmaceutical industry is the major factor driving the growth of the North American biologics safety testing market. Growing academic and government investments, rising demand for high-quality research tools for data reproducibility, increasing awareness among consumers about product safety, and the presence of major market players in this region are also driving the market for biologics safety testing in North America.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

  • By Respondent- Supply Side- 80%, Demand Side-20%
  • By Designation- CXOs- 20%, Executives - 25%, Mangers - 55%
  • By Region- North America -40%, Europe - 30%, APAC - 20%, LATAM & MEA- 10%

The Biologics Safety Testing market is dominated by a few globally established players such Charles River Laboratories, Inc. (US), Lonza (Switzerland), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and SGS SA (Switzerland), Eurofins Scientific (Luxembourg), Maravai Lifesciences (US), Associates of Cape Cod, Inc. (US), bioMerieux SA (France), Sartorius AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), and Nelson Laboratories, LLC (US), Bio-Rad Laboratories, Inc. (US) and QIAGEN (Germany),Agilent Technologies, Inc. (US), Pacific BioLabs (US), Microcoat Biotechnologie GmbH (Germany), PromoCell GmbH (Germany), FUJIFILM Wako Pure Chemical Corporation (Japan), and Almac Group (UK).

Research Coverage:

The report segments the Biologics Safety Testing market based on region (Asia Pacific, Europe, North America, Latin America and Middle East and Africa), product and service(consumables, services, and instruments), application(monoclonal antibodies manufacturing, vaccines manufacturing, blood and blood products manufacturing, cellular and gene therapy products manufacturing, and other applications.), and test types(endotoxin tests, sterility tests, mycoplasma tests, bioburden tests, virus safety tests, and residual host-cell proteins and DNA detection tests.). The report also provides a comprehensive review of market drivers, opportunities, challenges and trends in the Biologics Safety Testing market.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the Biologics Safety Testing market and provides them information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    • 1.2.2 MARKETS COVERED
    • FIGURE 1 BIOLOGICS SAFETY TESTING MARKET SEGMENTATION
    • 1.2.3 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 LIMITATIONS
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 BREAKDOWN OF PRIMARIES: BIOLOGICS SAFETY TESTING MARKET
    • 2.1.3 MARKET DATA ESTIMATION AND TRIANGULATION
    • 2.1.4 DATA TRIANGULATION
    • FIGURE 4 DATA TRIANGULATION METHODOLOGY
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • FIGURE 5 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION
    • FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL ANALYSIS-BASED ESTIMATION
    • FIGURE 7 BIOLOGICS SAFETY TESTING MARKET: FINAL CAGR PROJECTIONS (2021-2026)
    • FIGURE 8 BIOLOGICS SAFETY TESTING: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 9 BIOLOGICS SAFETY TESTING MARKET: SEGMENTAL ASSESSMENT
  • 2.3 INDUSTRY INSIGHTS
  • 2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 10 BIOLOGICS SAFETY TESTING MARKET SHARE, BY PRODUCT & SERVICE, 2020
    • FIGURE 11 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE BIOLOGICS SAFETY TESTING MARKET

4 PREMIUM INSIGHTS

  • 4.1 BIOLOGICS SAFETY TESTING MARKET OVERVIEW
    • FIGURE 14 GROWTH IN THE BIOLOGICS AND BIOSIMILARS MARKETS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION AND COUNTRY (2020)
    • FIGURE 15 MONOCLONAL ANTIBODIES MANUFACTURING SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
  • 4.3 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE
    • FIGURE 16 RESIDUAL HOST-CELL PROTEINS & DNA DETECTION TESTS SEGMENT TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 MARKET DYNAMICS
    • FIGURE 17 BIOLOGICS SAFETY TESTING MARKET: DRIVERS, OPPORTUNITIES, & CHALLENGES
    • 5.1.1 DRIVERS
      • 5.1.1.1 Growth in the biosimilars and biologics markets
    • FIGURE 18 TOTAL NUMBER OF NEW BIOLOGICS LICENSE APPLICATION APPROVALS, NDA APPROVALS, AND FILINGS (2005-2019)
    • TABLE 1 LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS IN THE US, 2019
      • 5.1.1.2 Growing concerns over cell culture contamination
      • 5.1.1.3 Rising biopharmaceuticals R&D activities and investments
    • FIGURE 19 R&D SPENDING BY PHRMA MEMBER COMPANIES, 2001-2019 (USD BILLION)
    • TABLE 2 PHARMACEUTICAL R&D SPENDING, BY COMPANY, 2019 VS. 2026 (USD BILLION)
    • 5.1.2 OPPORTUNITIES
      • 5.1.2.1 Emerging markets offer lucrative opportunities
      • 5.1.2.2 Increasing biopharmaceutical outsourcing
    • 5.1.3 CHALLENGES
      • 5.1.3.1 Dearth of skilled professionals
  • 5.2 IMPACT OF COVID-19 ON THE BIOLOGICS SAFETY TESTING MARKET
  • 5.3 PRICING ANALYSIS
    • TABLE 3 AVERAGE SELLING PRICE OF BIOLOGICS SAFETY TESTING PRODUCTS (2020)
  • 5.4 VALUE CHAIN ANALYSIS
    • FIGURE 20 VALUE CHAIN ANALYSIS OF THE BIOLOGICS SAFETY TESTING MARKET
  • 5.5 ECOSYSTEM ANALYSIS OF THE BIOLOGICS SAFETY TESTING MARKET
    • FIGURE 21 ECOSYSTEM ANALYSIS OF THE BIOLOGICS SAFETY TESTING MARKET
  • 5.6 PATENT ANALYSIS
    • FIGURE 22 NUMBER OF PATENTS GRANTED IN THE LAST 20 YEARS
    • TABLE 4 TOP 10 GRANTED PATENT OWNERS (US) IN THE LAST 20 YEARS
    • FIGURE 23 TOP 10 PLAYERS WITH THE HIGHEST NUMBER OF PATENT APPLICATIONS
  • 5.7 REGULATORY ANALYSIS
    • 5.7.1 US
    • 5.7.2 EUROPE
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 HIGH CAPITAL INVESTMENTS TO RESTRICT THE ENTRY OF NEW PLAYERS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY

6 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 6 BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 6.2 SERVICES
    • 6.2.1 INCREASING OUTSOURCING OF BIOLOGICS SAFETY TESTING BY PHARMA & BIOPHARMA COMPANIES TO DRIVE THE MARKET GROWTH
    • TABLE 7 BIOLOGICS SAFETY TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 8 NORTH AMERICA: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 9 EUROPE: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 10 ASIA PACIFIC: BIOLOGICS SAFETY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 CONSUMABLES
    • 6.3.1 REPEAT PURCHASE OF ASSAYS, KITS, & REAGENTS TO DRIVE THE MARKET GROWTH
    • TABLE 11 BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 12 NORTH AMERICA: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 13 EUROPE: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 14 ASIA PACIFIC: BIOLOGICS SAFETY TESTING CONSUMABLES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.4 INSTRUMENTS
    • 6.4.1 THE DEMAND FOR FULLY AUTOMATED INSTRUMENTS IS INCREASING IN RESEARCH APPLICATIONS
    • TABLE 15 BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 16 NORTH AMERICA: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 17 EUROPE: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 18 ASIA PACIFIC: BIOLOGICS SAFETY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE

  • 7.1 INTRODUCTION
    • TABLE 19 BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
  • 7.2 RESIDUAL HOST-CELL PROTEINS & DNA DETECTION TESTS
    • 7.2.1 RESIDUAL HOST-CELL PROTEINS & DNA DETECTION TESTS TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
    • TABLE 20 RESIDUAL HOST-CELL PROTEINS & DNA DETECTION TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 21 NORTH AMERICA: RESIDUAL HOST-CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 22 EUROPE: RESIDUAL HOST-CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 23 ASIA PACIFIC: RESIDUAL HOST-CELL PROTEINS & DNA DETECTION TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 MYCOPLASMA TESTS
    • 7.3.1 GROWING CONCERNS OVER CELL CULTURE CONTAMINATION TO DRIVE MARKET GROWTH
    • TABLE 24 MYCOPLASMA TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 25 NORTH AMERICA: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 26 EUROPE: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 27 ASIA PACIFIC: MYCOPLASMA TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 STERILITY TESTS
    • 7.4.1 STERILITY TESTING IS MANDATORY AT EVERY STAGE IN THE DRUG DEVELOPMENT AND PRODUCTION PROCESS
    • TABLE 28 STERILITY TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 29 NORTH AMERICA: STERILITY TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 30 EUROPE: STERILITY TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 31 ASIA PACIFIC: STERILITY TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.5 ENDOTOXIN TESTS
    • 7.5.1 INCREASING ADOPTION OF ENDOTOXIN TESTING FOR COVID-19 RESEARCH AND DRUG DEVELOPMENT TO FAVOR MARKET GROWTH
    • TABLE 32 ENDOTOXIN TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 33 NORTH AMERICA: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 34 EUROPE: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: ENDOTOXIN TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.6 VIRUS SAFETY TESTS
    • 7.6.1 HIGHER UPTAKE OF VIRUS SAFETY TESTS IN THE DEVELOPMENT OF VACCINES AND CELL & GENE THERAPY TO DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 36 VIRUS SAFETY TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 37 NORTH AMERICA: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 38 EUROPE: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: VIRUS SAFETY TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.7 BIOBURDEN TESTS
    • 7.7.1 INCREASING FOCUS ON DRUG SAFETY STANDARDS HAS INCREASED THE DEMAND FOR MICROBIOLOGICAL BIOBURDEN TESTING IN THE BIOLOGICS INDUSTRY
    • TABLE 40 BIOBURDEN TESTS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 41 NORTH AMERICA: BIOBURDEN TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 42 EUROPE: BIOBURDEN TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 43 ASIA PACIFIC: BIOBURDEN TESTS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

8 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 44 BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
  • 8.2 MONOCLONAL ANTIBODIES MANUFACTURING
    • 8.2.1 MONOCLONAL ANTIBODIES MANUFACTURING IS THE LARGEST APPLICATION SEGMENT
    • TABLE 45 BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES MANUFACTURING, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 46 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 47 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 48 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR MONOCLONAL ANTIBODIES MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 VACCINES MANUFACTURING
    • 8.3.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT THE GROWTH OF THIS SEGMENT
    • TABLE 49 BIOLOGICS SAFETY TESTING MARKET FOR VACCINES MANUFACTURING, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 50 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 51 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 52 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR VACCINES MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 BLOOD & BLOOD PRODUCTS MANUFACTURING
    • 8.4.1 SAFETY TESTING IS A CRITICAL PARAMETER IN THE REGULATORY APPROVAL FOR BLOOD PRODUCTS
    • TABLE 53 BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS MANUFACTURING, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 54 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 55 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 56 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR BLOOD & BLOOD PRODUCTS MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.5 CELLULAR & GENE THERAPY PRODUCTS MANUFACTURING
    • 8.5.1 INCREASING APPROVALS OF CELLULAR AND GENE THERAPY PRODUCTS TO DRIVE MARKET GROWTH
    • TABLE 57 BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS MANUFACTURING, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 58 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 59 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 60 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR CELLULAR & GENE THERAPY PRODUCTS MANUFACTURING, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.6 OTHER APPLICATIONS
    • TABLE 61 BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 62 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 63 EUROPE: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 64 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019-2026 (USD MILLION)

9 BIOLOGICS SAFETY TESTING MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 65 BIOLOGICS SAFETY TESTING MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 24 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
    • TABLE 66 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 67 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 68 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 69 NORTH AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 The US dominates the North American biologics safety testing market
    • TABLE 70 US: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 71 US: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 72 US: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Growing biopharmaceutical industry in the country to favor market growth
    • TABLE 73 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 74 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 75 CANADA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 76 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 77 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 78 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 79 EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Increasing investments in biologics to drive the market in Germany
    • TABLE 80 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 81 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 82 GERMANY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Increase in vaccine manufacturing to drive market growth
    • TABLE 83 UK: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 84 UK: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 85 UK: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Government initiatives to strengthen R&D activities will propel market growth
    • TABLE 86 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 87 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 88 FRANCE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Favorable government support to drive market growth in Italy
    • TABLE 89 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 90 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 91 ITALY: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Increase in biologics production to support market growth
    • TABLE 92 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 93 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 94 SPAIN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.3.6 REST OF EUROPE (ROE)
    • TABLE 95 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 96 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 97 REST OF EUROPE: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 25 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET SNAPSHOT
    • TABLE 98 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 99 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 China is the fastest-growing country for biologics safety testing products and services
    • TABLE 102 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 103 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 104 CHINA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Expansion of biologics manufacturing plants in Japan to support market growth
    • TABLE 105 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 106 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 107 JAPAN: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Growth in the biologics market to dive the adoption of biologics safety testing products and services in India
    • TABLE 108 BIOLOGICS AND BIOSIMILARS APPROVED IN INDIA, 2014-2019
    • TABLE 109 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 110 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 111 INDIA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
    • 9.4.4 REST OF ASIA PACIFIC
    • TABLE 112 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 113 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 114 REST OF ASIA PACIFIC: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 9.5 LATIN AMERICA
    • 9.5.1 GROWING APPROVAL OF BIOSIMILARS TO SUPPORT MARKET GROWTH
    • TABLE 115 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 116 LATIN AMERICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 117 LATIN AMERICA BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 INCREASING R&D INVESTMENTS AND THE DEVELOPMENT OF NEW DRUGS ARE KEY FACTORS DRIVING MARKET GROWTH
    • TABLE 118 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 119 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY TEST TYPE, 2019-2026 (USD MILLION)
    • TABLE 120 MIDDLE EAST & AFRICA: BIOLOGICS SAFETY TESTING MARKET, BY PRODUCT & SERVICE, 2019-2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 MARKET RANKING ANALYSIS
    • FIGURE 26 BIOLOGICS SAFETY TESTING MARKET RANKING, 2020
  • 10.3 COMPANY EVALUATION MATRIX
    • 10.3.1 STARS
    • 10.3.2 EMERGING LEADERS
    • 10.3.3 PERVASIVE PLAYERS
    • 10.3.4 PARTICIPANTS
    • FIGURE 27 BIOLOGICS SAFETY TESTING MARKET: COMPANY EVALUATION MATRIX, 2020
  • 10.4 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS
    • 10.4.1 PROGRESSIVE COMPANIES
    • 10.4.2 STARTING BLOCKS
    • 10.4.3 DYNAMIC COMPANIES
    • 10.4.4 RESPONSIVE COMPANIES
    • FIGURE 28 BIOLOGICS SAFETY TESTING: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS, 2020
  • 10.5 MARKET EVALUATION FRAMEWORK
    • TABLE 121 MARKET EVALUATION FRAMEWORK: EXPANSIONS & PRODUCT LAUNCHES ARE THE KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS
  • 10.6 COMPANY PRODUCT FOOTPRINT
    • TABLE 122 BIOLOGICS SAFETY TESTING MARKET: PRODUCT PORTFOLIO ANALYSIS
  • 10.7 COMPANY TEST TYPE FOOTPRINT
    • TABLE 123 BIOLOGICS SAFETY TESTING MARKET: TEST TYPE ANALYSIS
  • 10.8 COMPANY GEOGRAPHIC FOOTPRINT
    • TABLE 124 BIOLOGICS SAFETY TESTING MARKET: GEOGRAPHIC ANALYSIS
  • 10.9 COMPANY FOOTPRINT
    • TABLE 125 BIOLOGICS SAFETY TESTING MARKET: COMPANY FOOTPRINT
  • 10.10 COMPETITIVE SCENARIO
    • 10.10.1 BIOLOGICS SAFETY TESTING MARKET: PRODUCT LAUNCHES, JANUARY 2018-APRIL 2021
    • 10.10.2 BIOLOGICS SAFETY TESTING MARKET: DEALS, JANUARY 2018-APRIL 2021
    • 10.10.3 BIOLOGICS SAFETY TESTING MARKET: OTHER DEVELOPMENTS, JANUARY 2018-APRIL 2021

11 COMPANY PROFILES

  • (Business Overview, Products & services offered, Recent Developments, and Right to win)**
  • 11.1 KEY PLAYERS
    • 11.1.1 CHARLES RIVER LABORATORIES, INC.
    • TABLE 126 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 29 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
    • 11.1.2 LONZA
    • TABLE 127 LONZA: BUSINESS OVERVIEW
    • FIGURE 30 LONZA: COMPANY SNAPSHOT (2020)
    • 11.1.3 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 128 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 31 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
    • 11.1.4 MERCK KGAA
    • TABLE 129 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 32 MERCK KGAA: COMPANY SNAPSHOT (2020)
    • 11.1.5 SGS SA
    • TABLE 130 SGS SA: BUSINESS OVERVIEW
    • FIGURE 33 SGS SA: COMPANY SNAPSHOT (2020)
    • 11.1.6 EUROFINS SCIENTIFIC
    • TABLE 131 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW
    • FIGURE 34 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2020)
    • 11.1.7 WUXI APPTEC
    • TABLE 132 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 35 WUXI APPTEC: COMPANY SNAPSHOT (2020)
    • 11.1.8 ASSOCIATES OF CAPE COD, INC.
    • TABLE 133 ASSOCIATES OF CAPE COD: BUSINESS OVERVIEW
    • 11.1.9 BIOMERIEUX SA
    • TABLE 134 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 36 BIOMERIEUX SA: COMPANY SNAPSHOT (2020)
    • 11.1.10 SAMSUNG BIOLOGICS
    • TABLE 135 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
    • FIGURE 37 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2020)
    • 11.1.11 GENSCRIPT
    • TABLE 136 GENSCRIPT: BUSINESS OVERVIEW
    • FIGURE 38 GENSCRIPT: COMPANY SNAPSHOT (2020)
    • 11.1.12 SARTORIUS AG
    • TABLE 137 SARTORIUS AG: BUSINESS OVERVIEW
    • FIGURE 39 SARTORIUS AG: COMPANY SNAPSHOT (2020)
    • 11.1.13 ROCHE DIAGNOSTICS (A DIVISION OF F. HOFFMAN-LA ROCHE LTD.)
    • TABLE 138 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 40 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
    • 11.1.14 PACIFIC BIOLABS
    • TABLE 139 PACIFIC BIOLABS: BUSINESS OVERVIEW
    • 11.1.15 NELSON LABORATORIES, LLC (A PART OF SOTERA HEALTH)
    • TABLE 140 NELSON LABORATORIES: BUSINESS OVERVIEW
    • 11.1.16 AGILENT TECHNOLOGIES, INC.
    • TABLE 141 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
    • FIGURE 41 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2020)
    • 11.1.17 MARAVAI LIFESCIENCES
    • TABLE 142 MARAVAI LIFESCIENCES: BUSINESS OVERVIEW
    • FIGURE 42 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2020)
  • 11.2 OTHER PLAYERS
    • 11.2.1 QIAGEN
    • 11.2.2 BIO-RAD LABORATORIES, INC.
    • 11.2.3 MICROCOAT BIOTECHNOLOGIE GMBH
    • 11.2.4 INVIVOGEN
    • 11.2.5 PROMOCELL GMBH
    • 11.2.6 ACCUGEN LABORATORIES, INC.
    • 11.2.7 FUJIFILM WAKO PURE CHEMICAL CORPORATION
    • 11.2.8 ALMAC GROUP
  • *Details on Business Overview, Products & services offered, Recent Developments, and Right to win might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
Back to Top
전화 문의
F A Q